Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells $57,735.04 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 12,232 shares of the business’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.72, for a total transaction of $57,735.04. Following the sale, the chief executive officer directly owned 3,711,968 shares of the company’s stock, valued at $17,520,488.96. This represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.00, for a total transaction of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Stock Up 1.0%

NASDAQ:SOPH opened at $5.12 on Friday. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The company has a 50-day moving average of $4.75 and a 200 day moving average of $4.72. The firm has a market cap of $350.67 million, a PE ratio of -10.04 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.71 million during the quarter, compared to analysts’ expectations of $21.20 million. As a group, research analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC acquired a new position in shares of SOPHiA GENETICS during the third quarter valued at about $6,708,000. Royce & Associates LP acquired a new position in shares of SOPHiA GENETICS during the fourth quarter valued at about $2,009,000. Finally, 1492 Capital Management LLC acquired a new position in shares of SOPHiA GENETICS during the fourth quarter valued at about $973,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Strategic commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at a major NCI-designated center, which could drive recurring software volume and credibility with large U.S. health systems. Mount Sinai collaboration
• Positive Sentiment: Sector tailwind — coverage highlighting Mount Sinai’s use of AI to speed genomic testing reinforces demand for AI-driven genomics platforms like SOPHiA DDM, supporting adoption and long-term revenue potential. Healthcare IT News
• Positive Sentiment: Analyst interest — several firms have set $7.00 targets and issued buy opinions (e.g., Guggenheim, BTIG), giving investors an upside reference versus current levels.
• Neutral Sentiment: Insider selling activity — multiple insiders (CEO Jurgi Camblong, President Ross Muken and others) disclosed sales totaling tens of thousands of shares in mid-April. All trades were executed under pre-arranged Rule 10b5-1 plans and many were described as tax-withholding sales tied to vested awards, which reduces immediate governance concern but increases float. SEC Form 4 (example)
• Negative Sentiment: Underlying profitability risks — the company reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), with negative net margins and a substantial negative ROE. Analysts still expect FY losses (consensus around -0.96 EPS), highlighting ongoing path-to-profitability concerns that can cap multiple expansion. Earnings & metrics

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Guggenheim upped their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research increased their price target on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.